X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Hill-Rom Reports Improved Fiscal Third Quarter Results; Updates Full-Year Guidance

Yuvraj_pawp by Yuvraj_pawp
7th August 2014
in Market Moves

— Third quarter revenue of $398 million declined 6 percent versus prior year

— Adjusted diluted earnings per share for the third quarter of $0.59 compares to $0.57 in the prior year

— Reported diluted earnings per share for the third quarter of $0.45 compares to $0.39 per share in the prior year

— Year-to-date operating cash flow of $134 million compares to $168 million in the prior year

— Full year adjusted earnings per share are expected to be $2.20 to $2.24

 

Hill-Rom Holdings, Inc. (NYSE: HRC) announced financial results for its fiscal third quarter ended June 30, 2014 and narrowed its 2014 earnings outlook. Adjusted earnings per diluted share of $0.59 increased 4 percent from $0.57 in the prior year, while reported earnings per diluted share of $0.45 increased 15 percent from $0.39. Adjustments to reported earnings and EBITDA are detailed in the reconciliation schedules provided.

 

Hill-Rom’s quarterly revenue was $398 million, a 6 percent decrease compared to last year on a reported basis and a 7 percent decrease on a constant currency basis. Domestic revenue was $255 million, down 9 percent, while revenue outside the United States decreased 3 percent on a constant currency basis to $143 million.

 

Management Comments

 

“We are pleased to deliver adjusted earnings per share in line with our guidance, as well as expanded adjusted operating margin, despite continued revenue pressure across our portfolio,” said John Greisch, Hill-Rom President and Chief Executive Officer. “In addition, consistent with our strategic objective of portfolio diversification, we will continue to pursue disciplined business development activity such as the recently completed Trumpf Medical acquisition.”

 

Third Quarter Financial and Operational Results

 

— Revenue:

 

— North America. North America revenue declined 11 percent to $212 million. Capital revenue decreased 12 percent. Rental revenue declined 10 percent, or 6 percent excluding the impact of the third party reimbursed home care rental business, which Hill-Rom exited during the quarter.

 

— International. International segment revenue declined 3 percent to $120 million compared with the prior year (down 6 percent on a constant currency basis) with strength in Asia Pacific and Latin America, offset by lower revenue in the Middle East and Europe. Capital and rental revenue both declined an equivalent amount on a constant currency percentage basis.

 

— Surgical/Respiratory Care. Surgical/Respiratory Care revenue increased 7 percent to $66 million, due to strong results across all businesses.

— Year to date operating cash flow was $134 million compared to $168 million in the prior year.

 

— Year to date adjusted EBITDA was $194 million, compared to $223 million in the prior year.

 

— As previously announced, Hill-Rom completed the acquisition of Trumpf Medical on August 1 for approximately $250 million. The addition of Trumpf Medical’s line of integrated operating room solutions more than doubles Hill-Rom’s surgical portfolio with market leading operating room products. The acquisition also strengthens the Company’s geographic footprint in high-growth markets, including Asia/Pacific, the Middle East, Eastern Europe, and Latin America.

 

— Hill-Rom was recently awarded multi-year contracts across several acute care product categories. The agreements cover rental and capital products with several of the nation’s leading health systems and group purchasing organizations, including Hospital Corporation of America (HCA) and HealthTrust.

 

— During the quarter, Hill-Rom launched the VitalCough® System, its new cough assist product. The VitalCough System supplements Hill-Rom’s respiratory care portfolio, broadening its range of airway clearance solutions.

 

Please see the attached schedules for additional information, including condensed financial information, summary balance sheet, cash flow statement and reconciliations of GAAP to adjusted financial measures.

 

For a more complete review of Hill-Rom’s results, please refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014.

 

Financial Guidance Summary

 

Revenue: For the fourth quarter of fiscal 2014, Hill-Rom expects revenue growth of 6 to 8 percent. This reflects currency benefit of approximately 1 percent at current rates; and incremental revenue from the Trumpf Medical acquisition.

For full year fiscal 2014, Hill-Rom expects revenue decline of approximately 2 to 3 percent. This reflects currency benefit of approximately 1 percent at current rates; and incremental revenue from the Trumpf Medical acquisition.

Adjusted Earnings per Diluted Share: The Company’s guidance for fourth quarter adjusted earnings per diluted share is $0.68 to $0.72, which excludes acquisition-related intangible amortization expense.

 

Guidance for full year adjusted earnings per diluted share is $2.20 to $2.24, which excludes acquisition-related intangible amortization expense. For comparison, full year 2013 adjusted earnings per diluted share would have been $2.38, excluding acquisition-related intangible amortization expense.

 

Cash Flow: Hill-Rom expects cash flow from operations for the full year to be approximately $240 million, excluding cash outflows related to restructuring actions.

 

Adjusted EBITDA: Hill-Rom expects adjusted EBITDA for the full year to be approximately $280 million.

 

Discussion of Adjusted Financial Measures

 

Hill-Rom Holdings, Inc. routinely provides earnings per share results and guidance on an adjusted basis because the Company’s management believes that the presentation provides useful information to investors. In addition, we are providing adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) for the same reason. These measures exclude strategic developments, special charges or other unusual events. Such items may be highly variable, difficult to predict and of a size that sometimes have substantial impact on the Company’s reported operations for a period. Often, prospective quantification of such items is not feasible.

 

The Company also excludes expenses associated with the amortization of intangible assets associated with prior business acquisitions. This adjustment is made to allow investors to evaluate and understand operating trends excluding the non-cash impact of acquired intangible amortization on operating income, earnings per share and other measures that have historically included this expense.

 

Management uses these measures internally for planning, forecasting and evaluating the performance of the business. Investors should consider non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP.

 

Reconciliations of GAAP measures to adjusted measures appear in the financial tables of this release.

 

Conference Call Webcast and Dial-in Information

 

As previously announced, the Company will host a conference call and webcast today at 8:00 a.m. ET.

 

Webcast: To join the live webcast with audio, go to http://ir.hill-rom.com/events.cfm or http://www.media-server.com/m/p/ej2r4en2. The webcast slide deck will be posted to the Hill-Rom website prior to the webcast.

 

Conference Call Audio Only Dial-in information: To join the live conference call, dial 877-304-8969 domestic callers / 631-291-4543 international callers. The following Confirmation Code is required for both: 68877578. Callers will need to provide their name, company affiliation and telephone number to the conference operator. A recording of the webcast/call audio will be available for telephone replay through August 14, 2014, domestically at 855-859-2056 and internationally at 404-537-3406. For the replay, callers will need to use confirmation code 68877578. If you are unable to listen to the live webcast or the telephone replay, the webcast will be archived at http://ir.hill-rom.com/events.cfm.

 

About Hill-Rom Holdings, Inc.

 

Hill-Rom is a leading global medical technology company with more than 7,000 employees in over 100 countries. We partner with health care providers by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: Advancing Mobility, Wound Care and Prevention, Clinical Workflow, Surgical Safety and Efficiency, and Respiratory Health. Around the world, Hill-Rom’s people, products, and programs work towards one mission: Enhancing outcomes for patients and their caregivers.

Previous Post

Cardiome to hold second quarter 2014 financial results conference call on August 11

Next Post

Vanda Pharmaceuticals Reports Second Quarter 2014 Results

Related Posts

Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

8th April 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Market Moves

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

26th October 2021
My Personal Therapeutics and Pentavere receive EUREKA AI Therapeutics Funding to support the development of My Personal Therapeutics - digital therapeutics for Lung Cancer
Manufacturing

Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute

2nd August 2021
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

3rd December 2020
Next Post

Vanda Pharmaceuticals Reports Second Quarter 2014 Results

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In